(Q38617981)

4 September 2017

title

Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas (English)

1 reference

4 September 2017

Tali Siegal

1

1 reference

4 September 2017

language of work or name

1 reference

1 January 2016

1 reference

Advances and Technical Standards in Neurosurgery

4 September 2017

published in

1 reference

4 September 2017

issue

43

1 reference

4 September 2017

page(s)

91-108

1 reference

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

The role of MGMT testing in clinical practice: a report of the association for molecular pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

ATRX dysfunction induces replication defects in primary mouse cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

BRAF-V600E mutation in pediatric and adult glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Randomized clinical trials with biomarkers: design issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Phase III clinical trials that integrate treatment and biomarker evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Molecular markers in low-grade gliomas: predictive or prognostic?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Changing incidence and improved survival of gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Targeting BRAF in pediatric brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Recurring mutations found by sequencing an acute myeloid leukemia genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

An integrated genomic analysis of human glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Use of archived specimens in evaluation of prognostic and predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

DNA methylation landscapes: provocative insights from epigenomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Distinct methylation profiles of glioma subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Interlaboratory comparison of IDH mutation detection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Molecular predictors of outcome in low-grade glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Molecular neuro-oncology in clinical practice: a new horizon

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

IDH1 and IDH2 mutations in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-21359-0_4

10.1007/978-3-319-21359-0_4

31 March 2020

Identifiers

DOI

1 reference

4 September 2017

1 reference